Search research articles
Contact Us
Filters
Showing results (151-160 of 231) with videos related to
Page
of 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 31, 2022
More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma
Tomas Jelinek, Renata Bezdekova, David Zihala, et al.
Blood
|
July 21, 2021
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA
Michele Cavo, Jesus San-Miguel, Saad Z Usmani, et al.
Blood
|
September 17, 2009
The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients
Bruno Paiva, Maria-Belén Vidriales, Gema Mateo, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 19, 2025
Clinic-Biological Features and Prognostic Significance of MGUS-Like Myeloma who underwent to Autologous Stem Cell Transplantation
Borja Puertas, Elena Alejo, José J Pérez-Morán, et al.
Lancet (London, England)
|
December 15, 2019
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
Maria-Victoria Mateos, Michele Cavo, Joan Blade, et al.
Blood Cancer Journal
|
September 5, 2020
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
Meletios A Dimopoulos, Sagar Lonial, Darrell White, et al.
Haematologica
|
July 10, 2012
Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry
Roberto J Pessoa de Magalhães, María-Belén Vidriales, Bruno Paiva, et al.
Blood Cancer Journal
|
February 25, 2022
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
Adam D Cohen, Samir Parekh, Bianca D Santomasso, et al.
The Lancet. Haematology
|
March 28, 2020
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
Maria-Victoria Mateos, Hareth Nahi, Wojciech Legiec, et al.
The Lancet. Oncology
|
June 3, 2023
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
Heinz Ludwig, Evangelos Terpos, Niels van de Donk, et al.
Page
of 24
Search research articles
Search
Showing results (151-160 of 231) with videos related to
Sort By:
Page
of 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 31, 2022
More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma
Tomas Jelinek, Renata Bezdekova, David Zihala, et al.
Blood
|
July 21, 2021
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA
Michele Cavo, Jesus San-Miguel, Saad Z Usmani, et al.
Blood
|
September 17, 2009
The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients
Bruno Paiva, Maria-Belén Vidriales, Gema Mateo, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 19, 2025
Clinic-Biological Features and Prognostic Significance of MGUS-Like Myeloma who underwent to Autologous Stem Cell Transplantation
Borja Puertas, Elena Alejo, José J Pérez-Morán, et al.
Lancet (London, England)
|
December 15, 2019
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial
Maria-Victoria Mateos, Michele Cavo, Joan Blade, et al.
Blood Cancer Journal
|
September 5, 2020
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
Meletios A Dimopoulos, Sagar Lonial, Darrell White, et al.
Haematologica
|
July 10, 2012
Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry
Roberto J Pessoa de Magalhães, María-Belén Vidriales, Bruno Paiva, et al.
Blood Cancer Journal
|
February 25, 2022
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
Adam D Cohen, Samir Parekh, Bianca D Santomasso, et al.
The Lancet. Haematology
|
March 28, 2020
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
Maria-Victoria Mateos, Hareth Nahi, Wojciech Legiec, et al.
The Lancet. Oncology
|
June 3, 2023
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
Heinz Ludwig, Evangelos Terpos, Niels van de Donk, et al.
Page
of 24